U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06867094) titled 'A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis' on March 04.
Brief Summary: This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis.
This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks ...